Free Trial
NASDAQ:TARA

Protara Therapeutics Q4 2024 Earnings Report

Protara Therapeutics logo
$3.08 -0.04 (-1.13%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Protara Therapeutics EPS Results

Actual EPS
-$0.48
Consensus EPS
-$0.57
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Protara Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Protara Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Wednesday, March 5, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Protara Therapeutics' Q3 2025 earnings is scheduled for Tuesday, November 11, 2025

Protara Therapeutics Earnings Headlines

Equities Analysts Issue Forecasts for TARA FY2025 Earnings
Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Magnificent Seven—seven stocks he believes could deliver similar gains in under six years. His full breakdown is now live.tc pixel
Q3 EPS Estimate for Protara Therapeutics Lifted by Analyst
See More Protara Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Protara Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Protara Therapeutics and other key companies, straight to your email.

About Protara Therapeutics

Protara Therapeutics (NASDAQ:TARA), a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

View Protara Therapeutics Profile

More Earnings Resources from MarketBeat